Feasibility of Conducting Comparative Effectiveness Research and Validation of a Clinical Disease Activity Score for Chronic Nonbacterial Osteomyelitis
Authors' conclusion
The CNO CDAS was developed and validated for disease monitoring and assessment of treatment effectiveness.
Study context
- Population
- Consenting children or young adults with chronic nonbacterial osteomyelitis (CNO) enrolled into CHOIR140 received ≥1 consensus treatment plan (CTP) regimen
- Outcome
- CNO CDAS development and validation
Methodological detailsinternational registry (CHOIR), Delphi survey and nominal group technique, external validation surveys, Enrolment August 2018 to September 2020
- International registry (CHOIR)
- Delphi survey and nominal group technique
- External validation surveys
- Enrolment August 2018 to September 2020
Main finding
As reported in the abstract
- Change in clinical disease activity score (CDAS) significant in patients reporting disease worsening or improvement
- P < 0.001
Observational data: associations, not effects.
Further findings
Median
| Outcome | Before second-line treatment | After second-line treatment | P value |
|---|---|---|---|
| CDAS after initiating second-line treatmentsSignificant decrease | 12.0 (IQR 8.0–15.5) | 5.0 (IQR 3.0–12.0) | P = 0.002 |
Safety
- Second-line treatments well tolerated; psoriasis the most common adverse event
Original publication
Feasibility of Conducting Comparative Effectiveness Research and Validation of a Clinical Disease Activity Score for Chronic Nonbacterial Osteomyelitis. J Rheumatol. Published 1 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →